Sweden-based BioArctic AB (Nasdaq Stockholm: BIOA B) and Eli Lilly and Company have announced a research and collaboration agreement to combine BioArctic’s BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration, with BioArctic receiving USD 30 million upfront and eligible for up to USD 770 million in additional milestone payments. The deal is structured so that BioArctic generates the new drug candidate by engineering its blood-brain barrier delivery platform onto Lilly’s proprietary molecule, after which Lilly assumes full global responsibility for development and commercialization. The agreement is the fourth disclosed BrainTransporter partnership for BioArctic and signals continued large-pharma demand for the platform across multiple neurodegeneration programs.
The BrainTransporter platform uses the transferrin receptor to actively transport biologics and other modalities across the blood-brain barrier, a mechanism that preclinical data have indicated can increase antibody brain exposure by up to 70-fold compared with passive diffusion. The technology is applicable across multiple therapeutic areas and modalities beyond antibodies, and BioArctic has stated it is actively expanding the platform’s capability to transport additional molecule types. The identity of Lilly’s contributing molecule and the specific neurodegeneration indication have not been disclosed.
Under the agreement’s financial structure, BioArctic receives the USD 30 million upfront payment immediately upon signing. Milestone payments of up to USD 770 million are available across development, regulatory, and commercial stages. BioArctic is also entitled to tiered mid-single digit royalties on any future global net product sales. Lilly retains no co-development cost sharing with BioArctic; the Swedish company bears no development expenses beyond generating the initial drug candidate. BioArctic retains all BrainTransporter platform rights outside the scope of its four existing partnership agreements, preserving further out-licensing optionality.
The Lilly agreement closely mirrors the financial structure of BioArctic’s prior BrainTransporter deal with Novartis, which was signed in August 2025 and carried the same USD 30 million upfront and potential total value of approximately USD 802 million. Earlier BrainTransporter deals include a December 2024 global exclusive license to Bristol Myers Squibb (NYSE: BMY) covering the PyroGlutamate-amyloid-beta antibody program for USD 100 million upfront and up to USD 1.25 billion in milestones, and a 2024 research evaluation agreement with Eisai covering BAN2802. BioArctic’s ability to attract Lilly, Novartis, BMS, and Eisai to the same delivery platform within approximately two years indicates consistent cross-pharma validation of the technology’s perceived differentiation in central nervous system drug delivery, where blood-brain barrier penetration remains a primary development bottleneck.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/